ACRAF v. Graviti Pharmaceuticals: Trazodone Patent Action Dismissed With Prejudice
Italian pharmaceutical innovator Angelini ACRAF brought an infringement action against Indian generic maker Graviti Pharmaceuticals in Delaware over US8133893B2, covering trazodone hydrochloride in purified form. After 524 days of litigation, the parties jointly stipulated to dismiss the case with prejudice and with no costs to either side — a resolution that permanently closes the door on these specific claims.
Stipulated dismissal ends Angelini ACRAF’s trazodone infringement action
On 20 January 2023, Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A. — the Rome-headquartered pharmaceutical group and originator of trazodone — filed suit against Graviti Pharmaceuticals Private Limited in the District of Delaware (Case No. 1:23-cv-00068), alleging infringement of US8133893B2. That patent protects trazodone and trazodone hydrochloride in a purified crystalline form, a composition covering the active pharmaceutical ingredient at the core of Angelini’s branded antidepressant franchise.
The case closed on 27 June 2024 when both parties filed a Rule 41(a)(1)(A)(ii) stipulation of dismissal with prejudice. Under that mechanism, dismissal is effectuated without court order upon joint filing. The with-prejudice designation means ACRAF cannot re-assert the same claims against Graviti on the same patent, and the express waiver of appeal forecloses any future appellate challenge. Neither party will recover costs, disbursements, or attorneys’ fees.
The 524-day duration — filed January 2023, closed June 2024 — suggests the parties engaged in substantive pre-trial activity, possibly including Paragraph IV certification exchanges or claim construction proceedings, before reaching resolution. The public record does not disclose the terms of any underlying commercial arrangement. The simultaneous waiver of costs and appeal is consistent with a negotiated settlement, though no settlement agreement has been made public. Whether Graviti obtained a license, agreed to market-entry timing, or simply exited the product remains unknown from the docket.
Filing to Dismissed with Prejudice in 524 days
524 days — above the ~300-day median for ANDA-linked patent cases resolved pre-trial in Delaware
Dismissed with prejudice: what the stipulation means for both parties
Rule 41 stipulated dismissal — no court order required
Under FRCP 41(a)(1)(A)(ii), parties may jointly dismiss an action without a court order by filing a signed stipulation. Invoking Rule 41(c) extends this to counterclaims. The dismissal takes effect upon filing, meaning Judge Andrews had no discretion to modify terms. This is one of the cleanest procedural exits available in federal litigation, typically signalling that the parties reached a private resolution they preferred not to disclose on the record.
Joint stipulation, no court orderACRAF permanently bars re-litigation on these claims
Dismissal with prejudice operates as a final adjudication on the merits for res judicata purposes, meaning ACRAF cannot re-file this infringement action against Graviti on US8133893B2 for the same conduct. While this closes the enforcement action, it is consistent with a negotiated outcome — such as a licensing agreement or consent to delayed market entry — that ACRAF may have preferred over the uncertainty of continued litigation and trial.
Claims permanently resolvedGraviti exits the action with no public admission of liability
A stipulated dismissal carries no finding of infringement or validity. Graviti is not judicially bound by any adverse patent ruling, preserving its freedom to dispute US8133893B2 in other forums if needed. The no-costs provision means Graviti avoids any fee exposure. However, the with-prejudice term and appeal waiver suggest both sides committed to finality — Graviti’s path to market for purified trazodone HCl may have been addressed through private agreement.
No infringement findingSettlement signals possible licensed entry for purified trazodone generics
In the Hatch-Waxman and ANDA litigation context, with-prejudice stipulations following extended litigation typically reflect an agreed market-entry date or royalty-bearing license rather than unconditional withdrawal. For other generic manufacturers watching US8133893B2, the patent’s enforceability remains untested in court — no claim construction or validity ruling was issued, leaving the patent’s scope undetermined by judicial precedent. Competitors face continued uncertainty about FTO for purified trazodone formulations.
Patent scope judicially untestedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aziende Chimiche Riunite Angelini Francesco ACRAF SpA | Individual | Italian originator pharma group — holder of US8133893B2 covering purified trazodone HClSearch in Eureka ↗ |
| Defendant | Graviti Pharmaceuticals Private Limited | Individual | Indian generic pharmaceutical manufacturer targeted for purified trazodone HCl infringementSearch in Eureka ↗ |
| Plaintiff counsel | Karen L. Pascale | Attorney | Counsel for Aziende Chimiche Riunite Angelini Francesco ACRAF SpASearch in Eureka ↗ |
| Plaintiff counsel | Robert M. Vrana | Attorney | Counsel for Aziende Chimiche Riunite Angelini Francesco ACRAF SpASearch in Eureka ↗ |
| Plaintiff law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Aziende Chimiche Riunite Angelini Francesco ACRAF SpASearch in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation invokes both Rule 41(a)(1)(A)(ii) and Rule 41(c), ensuring that not only the plaintiff’s claims but also any counterclaims and affirmative defenses are extinguished simultaneously. The explicit with-prejudice designation and the bilateral waiver of appeal are legally significant: they create res judicata finality without any court finding on the merits of infringement or patent validity. The no-costs provision, symmetrically applied to both parties, is characteristic of negotiated resolutions rather than capitulation by either side.
US8133893B2 — purified trazodone hydrochloride crystalline composition
US8133893B2 (application number US12/513048, PCT national phase entry) protects trazodone and its hydrochloride salt in a purified form — likely covering a specific polymorph, purity threshold, or crystalline preparation process that distinguishes the composition from earlier-generation trazodone API. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) used as an antidepressant and sleep aid, with substantial global generics market activity. The national phase filing suggests this patent derives from an international PCT application, giving Angelini coordinated multi-jurisdictional protection.
For Angelini ACRAF — the originator of trazodone and owner of the Trittico/Desyrel franchise — US8133893B2 represents a strategic second-generation composition patent that extends IP exclusivity on the purified API beyond earlier compound patents. In the context of Hatch-Waxman litigation, such patents are routinely listed in the FDA Orange Book, triggering automatic 30-month stays upon Paragraph IV ANDA certification. The patent’s judicial validity has not been tested, making it a live enforcement tool that any generic manufacturer targeting this molecule must carefully evaluate.
Should your trazodone product trigger an FTO review of US8133893B2?
Any generic pharmaceutical company, contract API manufacturer, or specialty pharma group developing purified trazodone hydrochloride formulations — whether for ANDA filing or international regulatory submissions — should treat US8133893B2 as an active clearance requirement. Because this case resolved without a claim construction order or validity ruling, the patent’s enforceable scope remains entirely intact. The risk is particularly acute for companies at ANDA preparation, Paragraph IV certification, or commercial launch stage.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US8133893B2 against your product’s API specification, crystalline form, and purity profile, and identify the complete Angelini ACRAF patent family — including PCT siblings and Orange Book-listed continuations. Eureka can also surface inter partes review history and prior art landscapes to inform an invalidity strategy if freedom-to-operate is not achievable by design-around alone.
Run a freedom-to-operate analysis on US8133893B2 to assess your product’s exposure
Run FTO in Eureka →Similar trazodone and CNS small-molecule patent cases in Delaware
Cases involving purified pharmaceutical composition patents and Hatch-Waxman ANDA infringement actions in the Delaware District Court most relevant to US8133893B2.
What this case signals for the purified trazodone and CNS generics IP landscape
A with-prejudice exit after 524 days in Delaware is rarely accidental — here is what it means for the sector.
US8133893B2 remains judicially unchallenged — FTO risk persists for generics
No claim construction, no invalidity ruling, and no IPR challenge was resolved in this case. For any generic or specialty pharma company seeking to manufacture or market purified trazodone hydrochloride, US8133893B2 stands as an active enforcement risk. Companies should conduct FTO analysis before committing to product development or ANDA filing strategies.
Angelini ACRAF’s litigation posture supports active patent enforcement in Delaware
ACRAF’s willingness to file in Delaware — and sustain litigation for 524 days — signals a proactive enforcement strategy for its trazodone IP portfolio. Generic entrants targeting this molecule should anticipate similar actions. The Young Conaway Stargatt & Taylor firm, with deep Delaware patent litigation expertise, suggests ACRAF is prepared for substantive district court proceedings.
SpA v Graviti — key questions answered
The dismissal with prejudice resolves only the claims between ACRAF and Graviti — it does not invalidate US8133893B2 or limit ACRAF’s ability to enforce it against other defendants. Because no court ruled on validity or infringement, the patent retains full presumptive validity and remains an active enforcement risk for any other generic manufacturer.
The public docket identifies the cause of action as an infringement action involving trazodone and trazodone hydrochloride in purified form. While the case record does not explicitly confirm an ANDA Paragraph IV certification, the product category and defendant profile — an Indian generic manufacturer — are consistent with Hatch-Waxman litigation. The 30-month stay mechanism may have governed the litigation timeline.
Both parties expressly waived their right to appeal, which is unusual language in a Rule 41 stipulation and typically indicates the parties reached a broader commercial agreement they wished to make final and irrevocable. It prevents either party from later challenging the dismissal’s validity or the circumstances surrounding it at the Federal Circuit.
US8133893B2 protects trazodone and trazodone hydrochloride in purified form, likely a specific polymorph or crystalline preparation. As a composition patent potentially listed in the FDA Orange Book, it can trigger automatic 30-month ANDA stays. Because its claims have never been construed or tested for validity in court, any generic competitor must conduct independent FTO analysis before committing to this API.
Angelini ACRAF was represented by Karen L. Pascale and Robert M. Vrana of Young Conaway Stargatt & Taylor, LLP — a Delaware-based firm with a substantial pharmaceutical patent litigation practice. No defendant law firm or agents are listed in the public docket for Graviti Pharmaceuticals, which may suggest limited formal appearance before resolution.
PatSnap Eureka searches patents and litigation data to answer instantly.